What SHEMIM does
Reads scent as an early, honest health signal — prevention a person can own. This is our work.
What scent really is
Scent is molecular recognition, not perfume.
Long before there was a nose, cells learned to read molecules to know their world. That reading runs through the body still. The receptors we call olfactory are the largest gene family in the human genome, and they sit not only in the nose but throughout the body — in every tissue we have looked at, head to toe — where they read the body’s own chemistry, not the air’s. They are GPCRs, the same receptor class about a third of all modern medicine already acts on. Once scent is understood this way — as recognition — scent as medicine stops being a metaphor and becomes the literal claim.
Read early, and you prevent
A signal you can read before the clinic would.
The breath we exhale and the scent we give off move with the body’s state. Unlike most measures, they can be read non-invasively, continuously, and by the person themselves — which means they can speak early. That is the quiet radicalism of scent as medicine: not a new drug, but an earlier sentence.
- One breath test is already routine. Exhaled nitric oxide (FeNO) is read directly from breath to gauge airway inflammation and guide treatment.
- The breath carries a metabolic readout. The volatilome — the volatile fraction of the body’s metabolism — sends hundreds of molecules out on each exhale, reflecting pathways like oxidative stress.
- The body announces some illness by scent. From the acetone of a diabetic crisis to the volatile signature of Parkinson’s in skin oils — and losing the sense of smell itself predicts mortality.
Honest limit: only FeNO is in routine clinical use today; the wider promise is emerging, and a real share of breath molecules come from diet and environment, not the body. We say so plainly.
The receptors are becoming levers
Give the right tissue the right molecule, and it answers.
Because the body grew these receptors inside its own organs, they can be acted through. Switched on, an odour receptor on colon-cancer cells slowed their division and tipped them toward dying. In artery walls, the opposite: a receptor that smells a molecule in the blood switches on the inflammation behind heart disease — so there the medicine is to silence it. A receptor in the kidney listens for what gut bacteria make, and helps set blood pressure. The receptors are levers; medicine is learning which way to turn each.
These are early, preclinical findings — and the ligands act as molecules delivered to tissue, not aromas we inhale. We cite this frontier as evidence that the body acts on its own chemistry. It is not a treatment SHEMIM offers.
Where we draw the line
Two things, kept honestly distinct.
What we only cite
Scent-chemistry as therapy — the drug-target frontier above. Real, and others’ work. We point at it; we never claim to cure disease by smell.
How sure are we?
Every claim, tagged for how settled it is.
Established
- Olfactory receptors are the largest gene family in the human genome, and they are GPCRs — the receptor class about a third of all approved medicines already act on (Hauser et al., 2017).
- Their receptors appear far beyond the nose — across every tissue sampled in the GTEx atlas (some fifty sites, head to toe), none coming up empty (Flegel et al., 2013; Maßberg & Hatt, 2018).
- Exhaled nitric oxide (FeNO) is a standardized clinical breath test, read directly from breath to guide treatment (American Thoracic Society, 2021).
- Several conditions announce themselves by smell — acetone in diabetic crisis, maple-syrup urine, the fishy note of trimethylaminuria — taught in clinics for decades.
Documented · early
- Activating an odour receptor on colorectal-cancer cells (OR51B4) slowed their division and tipped them toward dying — in the lab (Weber & Hatt, 2017).
- In artery walls a receptor (OR6A2 / Olfr2) smells a blood molecule and drives the inflammation behind heart disease — so there the medicine is to silence it (Orecchioni & Ley, Science, 2022).
- A receptor in the kidney (Olfr78) reads short-chain fatty acids made by gut bacteria and helps regulate renin (Pluznick et al., 2013).
- Parkinson’s disease leaves a distinct volatile signature in skin sebum — found because one woman could smell it, later confirmed by mass spectrometry (Trivedi et al., 2019).
Emerging
- Ectopic olfactory receptors are being proposed as targets for nerve repair (Franco et al., Neural Regeneration Research, 2024).
- Machine-learning analysis of breath-VOC patterns can classify disease in research settings, though beyond FeNO these are not yet deployed (de Vries et al., Annals of Oncology, 2025).
Common questions
Frequently asked.
- Can a scent be a medicine?
- In a specific and growing sense, yes — once "scent" is understood as molecular recognition rather than perfume. Olfactory receptors expressed throughout the body act as drug targets: activating an odour receptor on colorectal-cancer cells slowed their division in the lab (Weber & Hatt, 2017), while blocking a receptor in artery walls is a strategy against atherosclerosis (Orecchioni & Ley, Science, 2022). About a third of approved drugs already act on the GPCR family that olfactory receptors belong to. These are preclinical findings — molecules delivered to tissue, not aromas inhaled.
- Are olfactory receptors only in the nose?
- No. Olfactory receptors are the largest gene family in the human genome and appear throughout the body — in every tissue sampled in the GTEx atlas, some fifty sites head to toe — where they read the body’s own chemistry rather than external odours (Flegel et al., 2013; Maßberg & Hatt, 2018).
- Can disease be detected by smell?
- Some can. Diabetic ketoacidosis, maple syrup urine disease and trimethylaminuria produce characteristic odours recognised clinically. Exhaled nitric oxide (FeNO) is a standardized breath test (ATS, 2021), and distinct volatile signatures have been identified in the sebum of people with Parkinson’s disease (Trivedi et al., 2019). Loss of the sense of smell itself predicts mortality (Pinto et al., 2014).
- Is "scent as medicine" proven?
- Partly. One breath biomarker (FeNO) is in routine clinical use; the rest is emerging and preclinical. SHEMIM’s own work is to read scent as an early health signal — prevention — and it keeps that distinct from the separate, cited frontier of using scent-receptors as drug targets. SHEMIM does not claim to cure disease by smell.
Selected sources
- Hauser et al. (2017), Nature Reviews Drug Discovery — ~34% of approved drugs act on GPCRs.
- Flegel et al. (2013); Maßberg & Hatt (2018), Physiological Reviews — ectopic olfactory receptors as body-wide chemosensors.
- American Thoracic Society (2021) — FeNO clinical practice guideline.
- Ratiu et al. (2023), Frontiers in Molecular Biosciences — the volatilome as metabolic readout.
- Trivedi et al. (2019), ACS Central Science — Parkinson’s sebum volatilome.
- Pinto et al. (2014), PLOS One — olfactory loss predicts 5-year mortality.
- Weber & Hatt (2017), PLOS One — OR51B4 / troenan in colorectal-cancer cells.
- Orecchioni & Ley (2022), Science — OR6A2 / Olfr2, octanal and atherosclerosis.
- Pluznick et al. (2013), PNAS — kidney Olfr78, gut SCFAs and renin.
- Franco et al. (2024), Neural Regeneration Research — ectopic ORs as nerve-repair targets.
This is conceptual architecture, built in the open.
SHEMIM is early — we distinguish clearly between evidence, inference, and hypothesis, and we look for people who can move specific threads from question to evidence.